What is Alpha Cognition's market cap?

Alpha Cognition (ACOG) has a market capitalization of $185.5M and trades on XNAS.

What is Alpha Cognition's revenue and profitability?

Alpha Cognition generated $10.8M in trailing twelve-month revenue with a net loss of $25.1M, representing a net margin of -232.2%. Gross margin stands at 89.3%, with free cash flow of -$30.4M. These figures are based on the Q1 2026 filing.

Who are Alpha Cognition's competitors?

Alpha Cognition's key competitors include Biogen Inc., Novartis AG, AbbVie Inc., and others. These companies compete in similar markets and product categories.

Who does Alpha Cognition partner with?

Alpha Cognition's notable partners include CMS International Development and Management Limited, Vimta Labs, Inc..

What subsidiaries does Alpha Cognition have?

Alpha Cognition's subsidiaries include Alpha Cognition Canada Inc., Alpha Cognition USA Inc..

Where is Alpha Cognition headquartered?

Alpha Cognition is headquartered in United States of America and employs approximately 5 people. It has been publicly traded since 2021.

Alpha Cognition

ACOG

Market cap

$185.52M+5.3%

Revenue$10.8M—

Net income-$25.1M-118%

Free cash flow-$30.4M-282%

EPS (diluted)-$1.58-21.5%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 14, 2026

Revenue$3.5MBeat by $111.1K EPS-$0.37Beat by $0.04

Read the full report

Next report

Aug 13, 2026 (in a month)

Revenue estimate$4.4M

EPS estimate-$0.40

Financials

Q1 2026

Income statement

See full

Revenue$3.5M+20.7%

Gross profit$3.3M+12.7%

Operating income-$8.1M-138%

Net income-$6.5M-276%

EPS (diluted)-$0.32-191%

Balance sheet

See full

Cash & equivalents$54.3M+100,638%

Total equity$57.5M+49.2%

Total assets$69.2M+42.5%

Cash flow

See full

Operating cash flow-$11.8M-477%

CapEx$1.3K-97.9%

Free cash flow-$11.8M-460%

Valuation & ratios

Valuation

See full

Market cap$185.52M+5.3%

P/S17.1×—

Profitability

See full

Gross margin89.3%—

Operating margin-250.1%—

Net margin-232.2%—

FCF margin-280.5%—

Returns & leverage

See full

Return on equity-52.4%-5.3pp

Current ratio12.6×-4.5×

Segments

By geography

See full

US$3.5M+910%

CN$30.0K-98.8%

By product

See full

Product Net$3.5M+910%

License$30.0K-98.8%

Competitors

By market cap

AbbVie$441.54B+33.2%

Biogen$29.4B+54.0%

Prothena Corporation plc$504.7M+49.1%

Anavex Life Sciences Corp.$250.2M-70.7%

Acumen Pharmaceuticals, Inc.$195.0M+178%

Alpha Cognition$185.5M+3.0%

Annovis Bio$83.0M+80.4%

Alzamend Neuro, Inc.$4.4M-47.1%

By revenue growth

AbbVie+9.5%

Biogen+1.2%

By net margin

Biogen14.3%-0.8pp

AbbVie5.79%-1.5pp

Alpha Cognition-232.24%—

Profile

Alpha Cognition Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for neurodegenerative diseases, specifically Alzheimer's disease and cognitive impairment from traumatic brain injury. The company's core value proposition centers on its proprietary pro-drug technology designed to enhance drug delivery to the brain while minimizing gastrointestinal side effects common in existing therapies.

Competitive position

The company is an emerging commercial-stage player in the Alzheimer's market, positioning its lead product as a better-tolerated alternative to established generic and branded acetylcholinesterase inhibitors.

GeographiesUnited States, Asia, Europe, Latin America

Customer segmentsHealthcare Providers, Long-term Care Facilities, Pharmaceutical Distributors

Business modelResearch and Development, Licensing, Direct Sales

SuppliersContract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Active Pharmaceutical Ingredient (API) suppliers

CustomersLong-term care pharmacies, Pharmacy Benefit Managers (PBMs), Medicare payors, International pharmaceutical distributors

CountryUnited States of America

Listed2021

Employees5.0

CEOMichael E. McFadden

SectorBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

IndustryBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Websitealphacognition.com

FilingsSEC EDGAR

Ask your AI about Alpha Cognition.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alpha Cognition's market cap?: Alpha Cognition (ACOG) has a market capitalization of $185.5M and trades on XNAS.
What is Alpha Cognition's revenue and profitability?: Alpha Cognition generated $10.8M in trailing twelve-month revenue with a net loss of $25.1M, representing a net margin of -232.2%. Gross margin stands at 89.3%, with free cash flow of -$30.4M. These figures are based on the Q1 2026 filing.
Who are Alpha Cognition's competitors?: Alpha Cognition's key competitors include Biogen Inc., Novartis AG, AbbVie Inc., and others. These companies compete in similar markets and product categories.
Who does Alpha Cognition partner with?: Alpha Cognition's notable partners include CMS International Development and Management Limited, Vimta Labs, Inc..
What subsidiaries does Alpha Cognition have?: Alpha Cognition's subsidiaries include Alpha Cognition Canada Inc., Alpha Cognition USA Inc..
Where is Alpha Cognition headquartered?: Alpha Cognition is headquartered in United States of America and employs approximately 5 people. It has been publicly traded since 2021.